Cite
HARVARD Citation
Yang, W. et al. (2022). Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial. Diabetes, obesity & metabolism. 24 (8), pp. 1522-1533. [Online].